The pathological course of AD includes the intracellular deposition of phosphorylated tau, extracellular accumulation, and deposition of amyloid beta (Aβ) and structural brain atrophy (hippocampus)(Brayne et al., 2009; Jack et al., 2018) research generally focuses on the biomarkers of AD (PET imaging, CSF, and/or plasma levels of Aβ and tau, MRI of hippocampal atrophy), to predict the future development of the disease. This evidence concerns the gene MAPT and Alzheimer disease.